Peter Luke Santa Maria1, Sungwoo Kim2, Yunzhi Peter Yang2,3,4. 1. a Department of Otolaryngology , Head and Neck Surgery, Stanford University , Stanford , CA , USA . 2. b Department of Orthopedic Surgery , Stanford University , Stanford , CA , USA . 3. c Department of Materials Science and Engineering , Stanford University , Stanford , CA , USA , and. 4. d Department of Bioengineering , Stanford University , Stanford , CA , USA.
Abstract
CONTEXT: Heparin-binding epidermal growth factor like growth factor (HB-EGF) is an emerging therapeutic for the regeneration of the tympanic membrane (TM). OBJECTIVE: Our aim was to determine whether the doses of HB-EGF delivered in a sustained release hydrogel into a middle ear mouse model, would be measurable in the systemic circulation. We also aimed to observe, in the scenario that the intended dose was absorbed directly into the circulation, whether these levels could be measured above the background levels of HB-EGF in the circulation. METHODS: A total of 12 mice had transtympanic injections of 5 μg/ml of HB-EGF contained within a previously described novel hydrogel vehicle, while another 12 mice had intravenous delivery of 10 μg/kg of HB-EGF. Intravenous blood samples were collected at 0-, 3-, 24-, 168-, 288- and 720-h post-injection. A double-antibody sandwich one-step process enzyme-linked immunosorbent assay (ELISA) was used to determine the level of HB-EGF in the serum. RESULTS: No mice in the transtympanic administration group and no mice in the intravenous administration group were found to have blood level measured above that in the controls. DISCUSSION: The inability of the positive control to measure levels above background, suggest the total dose used in our studies, even if 100% absorbed into the system circulation is insignificant. CONCLUSIONS: HB-EGF at the doses and delivery method proposed for treatment of chronic TM perforation in a mouse model are likely to have no measurable systemic effect.
CONTEXT: Heparin-binding epidermal growth factor like growth factor (HB-EGF) is an emerging therapeutic for the regeneration of the tympanic membrane (TM). OBJECTIVE: Our aim was to determine whether the doses of HB-EGF delivered in a sustained release hydrogel into a middle earmouse model, would be measurable in the systemic circulation. We also aimed to observe, in the scenario that the intended dose was absorbed directly into the circulation, whether these levels could be measured above the background levels of HB-EGF in the circulation. METHODS: A total of 12 mice had transtympanic injections of 5 μg/ml of HB-EGF contained within a previously described novel hydrogel vehicle, while another 12 mice had intravenous delivery of 10 μg/kg of HB-EGF. Intravenous blood samples were collected at 0-, 3-, 24-, 168-, 288- and 720-h post-injection. A double-antibody sandwich one-step process enzyme-linked immunosorbent assay (ELISA) was used to determine the level of HB-EGF in the serum. RESULTS: No mice in the transtympanic administration group and no mice in the intravenous administration group were found to have blood level measured above that in the controls. DISCUSSION: The inability of the positive control to measure levels above background, suggest the total dose used in our studies, even if 100% absorbed into the system circulation is insignificant. CONCLUSIONS:HB-EGF at the doses and delivery method proposed for treatment of chronic TM perforation in a mouse model are likely to have no measurable systemic effect.
Authors: Y Murayama; J Miyagawa; S Higashiyama; S Kondo; M Yabu; K Isozaki; Y Kayanoki; S Kanayama; Y Shinomura; N Taniguchi Journal: Gastroenterology Date: 1995-10 Impact factor: 22.682
Authors: Intira Coowanitwong; Susan K Keay; Karthika Natarajan; Tushar S Garimella; Clifford W Mason; David Grkovic; Kenneth S Bauer Journal: Pharm Res Date: 2007-08-01 Impact factor: 4.200
Authors: J A Abraham; D Damm; A Bajardi; J Miller; M Klagsbrun; R A Ezekowitz Journal: Biochem Biophys Res Commun Date: 1993-01-15 Impact factor: 3.575
Authors: Peter Luke Santa Maria; Peter Gottlieb; Chloe Santa Maria; Sungwoo Kim; Sunil Puria; Yunzhi Peter Yang Journal: Tissue Eng Part A Date: 2017-02-24 Impact factor: 3.845
Authors: Daniel M Beswick; Chloe Santa Maria; Noel F Ayoub; Robson Capasso; Peter Luke Santa Maria Journal: Eur Arch Otorhinolaryngol Date: 2017-11-29 Impact factor: 2.503
Authors: Jing Chen; Laurent A Bekale; Kelly M Khomtchouk; Anping Xia; Zhixin Cao; Shoucheng Ning; Susan J Knox; Peter L Santa Maria Journal: Sci Rep Date: 2020-10-15 Impact factor: 4.379